Standard
A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease : Final results. / Lassen, U; Sorensen, M; Jensen, PB; Langer, SW; Jensen, BB; Jeppesen, N; Rytter, C; Mellemgaard, A; Hansen, O; Osterlind, K.
In:
Journal of Clinical Oncology, Vol. 22, No. 14, 15.07.2004, p. 667S-667S.
Research output: Contribution to journal › Conference article › Research › peer-review
Harvard
Lassen, U, Sorensen, M, Jensen, PB, Langer, SW, Jensen, BB, Jeppesen, N, Rytter, C, Mellemgaard, A, Hansen, O & Osterlind, K 2004, 'A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results.', Journal of Clinical Oncology, vol. 22, no. 14, pp. 667S-667S.
APA
Lassen, U., Sorensen, M., Jensen, PB., Langer, SW., Jensen, BB., Jeppesen, N., Rytter, C., Mellemgaard, A., Hansen, O., & Osterlind, K. (2004). A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results. Journal of Clinical Oncology, 22(14), 667S-667S.
Vancouver
Lassen U, Sorensen M, Jensen PB, Langer SW, Jensen BB, Jeppesen N et al. A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results. Journal of Clinical Oncology. 2004 Jul 15;22(14):667S-667S.
Author
Lassen, U ; Sorensen, M ; Jensen, PB ; Langer, SW ; Jensen, BB ; Jeppesen, N ; Rytter, C ; Mellemgaard, A ; Hansen, O ; Osterlind, K. / A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease : Final results. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 14. pp. 667S-667S.
Bibtex
@inproceedings{4327b518a22c46869abc9a97ac52e293,
title = "A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results.",
author = "U Lassen and M Sorensen and PB Jensen and SW Langer and BB Jensen and N Jeppesen and C Rytter and A Mellemgaard and O Hansen and K Osterlind",
year = "2004",
month = jul,
day = "15",
language = "English",
volume = "22",
pages = "667S--667S",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",
note = "40th Annual Meeting of the American-Society-of-Clinical-Oncology ; Conference date: 05-06-2004 Through 08-06-2004",
}
RIS
TY - GEN
T1 - A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease
T2 - 40th Annual Meeting of the American-Society-of-Clinical-Oncology
AU - Lassen, U
AU - Sorensen, M
AU - Jensen, PB
AU - Langer, SW
AU - Jensen, BB
AU - Jeppesen, N
AU - Rytter, C
AU - Mellemgaard, A
AU - Hansen, O
AU - Osterlind, K
PY - 2004/7/15
Y1 - 2004/7/15
M3 - Conference article
VL - 22
SP - 667S-667S
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 14
Y2 - 5 June 2004 through 8 June 2004
ER -
